{"schema":"hottub-news/prospects/v1","item":{"id":"n_vwgso7qfsbcd4fob4rga","title":"Perioperative IMFINZI® (durvalumab) approved in the US in novel regimen with neoadjuvant enfortumab vedotin-ejfv for patients with muscle-invasive bladder cancer","title_en":null,"url":"https://www.timesargus.com/news/business/perioperative-imfinzi-durvalumab-approved-in-the-us-in-novel-regimen-with-neoadjuvant-enfortumab-vedotin-ejfv/article_f3dcea46-595d-595c-8090-0ad71943ef2d.html","outlet":"Barre Montpelier Times Argus","published":"2026-11-13T23:40:05Z","sponsored":false,"page":"https://hottub.news/articles/n_vwgso7qfsbcd4fob4rga"},"prospects":[{"name":"Barre Montpelier Times Argus","kind":"organization","role":"outlet","website":"https://timesargus.com/","entity":"wikidata:Q4863287","source":"https://www.timesargus.com/news/business/perioperative-imfinzi-durvalumab-approved-in-the-us-in-novel-regimen-with-neoadjuvant-enfortumab-vedotin-ejfv/article_f3dcea46-595d-595c-8090-0ad71943ef2d.html","note":"Published: Perioperative IMFINZI® (durvalumab) approved in the US in novel regimen with neoadjuvant enfortumab vedotin-ejfv for patients with muscle-invasive bladder cancer (2026-11-13)","reason":"Published “Perioperative IMFINZI® (durvalumab) approved in the US in novel regimen with neoadjuvant enfortumab vedotin-ejfv for patients with muscle-invasive bladder cancer” on 2026-11-13","group":"Outlet","add_url":"https://crm.joinhottub.com/relationships/add#name=Barre%20Montpelier%20Times%20Argus&kind=organization&website=https%3A%2F%2Ftimesargus.com%2F&source=https%3A%2F%2Fwww.timesargus.com%2Fnews%2Fbusiness%2Fperioperative-imfinzi-durvalumab-approved-in-the-us-in-novel-regimen-with-neoadjuvant-enfortumab-vedotin-ejfv%2Farticle_f3dcea46-595d-595c-8090-0ad71943ef2d.html&entity=wikidata%3AQ4863287&note=Published%3A%20Perioperative%20IMFINZI%C2%AE%20%28durvalumab%29%20approved%20in%20the%20US%20in%20novel%20regimen%20with%20neoadjuvant%20enfortumab%20vedotin-ejfv%20for%20patients%20with%20muscle-invasive%20bladder%20cancer%20%282026-11-13%29","propose":{"name":"Barre Montpelier Times Argus","kind":"organization","reason":"Published “Perioperative IMFINZI® (durvalumab) approved in the US in novel regimen with neoadjuvant enfortumab vedotin-ejfv for patients with muscle-invasive bladder cancer” on 2026-11-13","requestId":"news:n_vwgso7qfsbcd4fob4rga:wikidata:Q4863287:355e9574","website":"https://timesargus.com/","sourceUrl":"https://www.timesargus.com/news/business/perioperative-imfinzi-durvalumab-approved-in-the-us-in-novel-regimen-with-neoadjuvant-enfortumab-vedotin-ejfv/article_f3dcea46-595d-595c-8090-0ad71943ef2d.html","entity":"wikidata:Q4863287"}}],"someone_else":{"source":"https://www.timesargus.com/news/business/perioperative-imfinzi-durvalumab-approved-in-the-us-in-novel-regimen-with-neoadjuvant-enfortumab-vedotin-ejfv/article_f3dcea46-595d-595c-8090-0ad71943ef2d.html","note":"In the news: Perioperative IMFINZI® (durvalumab) approved in the US in novel regimen with neoadjuvant enfortumab vedotin-ejfv for patients with muscle-invasive bladder cancer (Barre Montpelier Times Argus, 2026-11-13)"},"crm":{"name":"CRM by Hottub","add":"Open add_url in a browser: CRM by Hottub's add form, filled in. Nothing is saved until the person presses Add.","mcp":"https://crm.joinhottub.com/api/crm/mcp","tool":"propose_relationship","propose":"If you're connected to CRM by Hottub's MCP server with proposal access, call propose_relationship with `propose` as its arguments. An owner approves it before anything is added. Keep the arguments as given: retries reuse requestId."}}